Fierce Biotech: Biogen maps out $1B biobucks deal with RNAi-focused City Therapeutics
Fierce Biotech: Prothena reburies drug after 2nd swing at rare disease misses, plans 'substantial' layoffs
Vibe Bio | The Science of Drug Development: Lessons from a Pioneer in Pharmaceutical Decision-Making
Forbes: Somite AI Raises $47M Series A To Reinvent Cell Replacement Therapy
Fierce Pharma: Novartis expands strategic collaboration with Shanghai Pharma in China to cover eye drugs
Fierce Pharma: FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset
Endpoint News: CHMP clears path for GSK’s Blenrep relaunch, recommends four other drugs
Vibe Bio Webinar: Bottlenecks to Breakthroughs AI in BD&L
In a significant and promising move, newly-appointed FDA Commissioner Marty Makary, M.D., M.P.H., recently shared his vision for using generative AI to accelerate scientific reviews.
While it may sound like a technical upgrade, the implications could be significant—particularly for rare disease communities and early-stage biotechs navigating the challenges of drug development.
Whether you're a founder, clinician, or parent of someone affected by a rare disease, the goals are aligned: bring safe, effective treatments to patients faster. And to do that, we believe the FDA functions best when it leads with:
Speed – Timely, thorough feedback can save lives and preserve cash runway for small biotechs.
Transparency – Clear, consistent regulatory rationale helps programs adapt early.
Predictability – Fewer surprises mean less risk and better development decisions.
To achieve these goals, the FDA and biopharma could benefit from deploying generative AI agents as partners to human reviewers. We're excited to see the FDA embrace this vision and are committed to supporting the ecosystem with solutions that make it a reality.
Do you have thoughts or want to learn more about how Vibe Bio is building toward this future? Get in touch.
In a recent webinar, Yael Weiss, a seasoned BD&L professional and current CEO of Mahzi Therapeutics, shared her insights on building high-performing business development teams and navigating the evolving biotech landscape. With a background in rare diseases and experience spanning Genzyme, Merck, and Ultragenyx, Yael identified five key characteristics for high-performing business development teams: strong scientific acumen, business transaction expertise, cross-functional collaboration across therapeutic areas, robust technology systems to track interactions and relationship history, and clear strategic alignment with internal therapeutic priorities.
Key webinar takeaways:
Industry Shift: Pharma companies increasingly embrace external innovation, focusing on diverse modalities, such as RNA, DNA, and gene therapy.
Geographic Trends: Chinese biotech is rising, driven by US-trained scientists and strong local capabilities, now accounting for ~1/3 of transactions.
AI in BD&L: AI accelerates screening and prioritization, cutting timelines from months to hours, though human expertise remains vital for deep diligence.
Watch the webinar on demand for more insights into the trends and strategies shaping the BD&L landscape.
In a recent exchange with a diagnostic accelerator focused on Alzheimer’s, the team shared updates from the front lines—indicating how the field is evolving and where AI may play a role.
The group is spearheading efforts in digital diagnostics. Several challenges persist, however, including:
Integrating multimodal data (for example, blood, speech, and EHR data) to deliver accurate, early diagnostics
Identifying which biomarkers are truly predictive vs. merely correlative
Harmonizing inconsistent data across global cohort studies
Validating new diagnostics without access to large, standardized datasets
Scaling expert-level diligence with limited human resources
As we talked through these challenges, the potential value of AI analysis emerged as a way to replicate the thought processes of domain experts across regulatory, clinical, and scientific disciplines. For this initiative, AI could help them evaluate, validate, and scale Alzheimer’s diagnostics more efficiently—especially as precision medicine continues to evolve.
Coming up June 16-19, we’ll be at BIO 2025, an international convention representing the full biotech ecosystem. BIO brings together 20,000 industry leaders from around the world to help people make connections and build relationships in biotechnology. See you in Boston this June!
Connect with Alok Tayi, PhD, co-founder and CEO of Vibe Bio, at the event—schedule a meeting now.
If you’ve read our newsletter before, you already know we use Discord to stay connected. It’s a great way to share interests and photos from trips. This month, Alok Tayi, PhD, went with his family to Italy. It was a beautiful trip!
Community building is a top priority for us! Learn about how we're driving our mission to find every cure for every disease and join the conversation! Follow us on social media to stay up-to-date with the latest news and updates from our community.
Tell us what else you’d like to see in future editions of the newsletter (on social media or via email). We’d love to hear from you!
Sincerely,
The Vibe Bio Team
#EveryCureforEveryCommunity
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.